multiple indications (Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, hidradenitis suppurativa, juvenile idiopathic arthritis)
Rheumatology · 2020–2021
3decisions
1medicine
3carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Biosimilar to Humira for treatment of severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex… | Jul 2021 | Recommended with restriction | input received |
| adalimumab Biosimilar brand of adalimumab for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile… | Mar 2020 | Recommended | input received Colitis Australia |
| adalimumab Multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex refractory… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
Who spoke
Colitis Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.